Entrada’s 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate back on track after the FDA lifted a more than two-year-long hold.
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate back on track after the FDA lifted a more than two-year-long hold.
